These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20338615)

  • 1. Intratumoral heterogeneity of HER-2 gene amplification and protein overexpression in breast cancer.
    Wu JM; Halushka MK; Argani P
    Hum Pathol; 2010 Jun; 41(6):914-7. PubMed ID: 20338615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
    Gong Y; Booser DJ; Sneige N
    Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification.
    Arnould L; Arveux P; Couturier J; Gelly-Marty M; Loustalot C; Ettore F; Sagan C; Antoine M; Penault-Llorca F; Vasseur B; Fumoleau P; Coudert BP
    Clin Cancer Res; 2007 Nov; 13(21):6404-9. PubMed ID: 17975153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?
    Sauer T; Wiedswang G; Boudjema G; Christensen H; Karesen R
    APMIS; 2003 Mar; 111(3):444-50. PubMed ID: 12752225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Negative genic switch of HER-2 in the primary tumor instead of the synchronous metastatic nodal lesions after neoadjuvant chemotherapy in a patient with primary HER2-positive breast cancer.
    Chen HR; Wu YT; Yu QB; Yang YY; Wei YX; Li HY; Wu KN; Kong LQ
    World J Surg Oncol; 2017 Oct; 15(1):189. PubMed ID: 29052527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of metastatic breast cancer with outgrowth of HER2-negative cells after eradication of HER2-positive cells by humanized anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel.
    Kunitomo K; Inoue S; Ichihara F; Kono K; Fujii H; Matsumoto Y; Ooi A
    Hum Pathol; 2004 Mar; 35(3):379-81. PubMed ID: 15017597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stability of HER2-positive status in breast carcinoma: a comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment.
    Xiao C; Gong Y; Han EY; Gonzalez-Angulo AM; Sneige N
    Ann Oncol; 2011 Jul; 22(7):1547-1553. PubMed ID: 21239403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment].
    Ohsako T; Inoue K; Nagamoto N; Yoshida Y; Nakahara O
    Gan To Kagaku Ryoho; 2006 Sep; 33(9):1301-3. PubMed ID: 16969029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Markedly effective regimen using bi-weekly trastuzumab and paclitaxel in an advanced breast cancer with multiple liver metastases].
    Rai Y; Takahama T; Sagara Y; Sagara Y; Matsuyama Y; Ando M; Sagara Y; Ooi Y
    Gan To Kagaku Ryoho; 2006 Sep; 33(9):1297-300. PubMed ID: 16969028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment and characterization of a cell line (BTIC) including HER-2-positive cells derived from pleural effusion of recurrent breast invasive ductal carcinoma, scirrhous type.
    Ninomiya K; Ohi S; Tabei I; Jin S; Tachibana T; Yamashita S; Yanaga K; Hashimoto H
    Hum Cell; 2007 Aug; 20(3):85-90. PubMed ID: 17645728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of HER-2-positive advanced inflammatory breast cancer with invasive micropapillary component showing a clinically complete response to concurrent trastuzumab and paclitaxel treatment.
    Shigematsu H; Nakamura Y; Tanaka K; Shiotani S; Koga C; Kawaguchi H; Nishimura S; Taguchi K; Nishiyama K; Ohno S
    Int J Clin Oncol; 2010 Dec; 15(6):615-20. PubMed ID: 20473628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.
    Gonzalez-Angulo AM; Hortobágyi GN; Esteva FJ
    Oncologist; 2006 Sep; 11(8):857-67. PubMed ID: 16951389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of locoregional outcome in HER2-overexpressing breast cancer treated with neoadjuvant chemotherapy.
    Arsenault D; Hurley J; Takita C; Reis IM; Zhao W; Rodgers S; Wright JL
    Am J Clin Oncol; 2015 Aug; 38(4):348-52. PubMed ID: 23799288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer.
    Simon R; Nocito A; Hübscher T; Bucher C; Torhorst J; Schraml P; Bubendorf L; Mihatsch MM; Moch H; Wilber K; Schötzau A; Kononen J; Sauter G
    J Natl Cancer Inst; 2001 Aug; 93(15):1141-6. PubMed ID: 11481385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The requirements to clinicopathology about targeted therapy for breast cancer].
    Jiang ZF; Shen G
    Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):435-7. PubMed ID: 17845752
    [No Abstract]   [Full Text] [Related]  

  • 17. Successful treatment of biphasic metaplastic sarcomatoid carcinoma of the breast by evaluation of immunohistochemical markers.
    Chien T; Chou J; Chang T; Lin C
    Hematol Oncol Stem Cell Ther; 2010; 3(2):89-93. PubMed ID: 20543543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic breast cancer of HER2 scored 2+ by IHC and HER2 gene amplification assayed by FISH has a good response to single agent therapy with trastuzumab: a case report.
    Takahashi M; Inoue K; Goto R; Tamura M; Taguchi K; Takahashi H; Suzuki H; Katsushige K; Ogita M
    Breast Cancer; 2003; 10(2):170-4. PubMed ID: 12736573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of metastatic breast cancer with HER2 gene amplification that responded completely to single agent trastuzumab.
    Tsutani Y; Ohsumi S; Aogi K; Taira N; Kataoka M; Hamamoto Y; Nishimura R; Takashima S
    Breast Cancer; 2006; 13(4):374-7. PubMed ID: 17146166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy.
    Brunelli M; Manfrin E; Martignoni G; Bersani S; Remo A; Reghellin D; Chilosi M; Bonetti F
    Am J Clin Pathol; 2008 Jun; 129(6):907-11. PubMed ID: 18480007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.